About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Summary

4521
TSE Prime
KAKEN PHARMACEUTICAL CO.,LTD.
4,195
JPY
-270
(-6.05%)
Apr 9, 3:30 pm JST
28.85
USD
Apr 9, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
11.5
PBR
1.04
Yield
4.53%
Margin Trading Ratio
6.68
Stock Price
Apr 9, 2025
Opening Apr 9, 9:00 am
4,465 JPY 30.61 USD
Previous Close Apr 8
4,465 JPY 30.26 USD
High Apr 9, 9:00 am
4,485 JPY 30.75 USD
Low Apr 9, 1:26 pm
4,095 JPY 28.25 USD
Volume
450,500
Trading Value
1.90B JPY 0.01B USD
VWAP
4215.29 JPY 29.0 USD
Minimum Trading Value
419,500 JPY 2,885 USD
Market Cap
0.19T JPY 1.33B USD
Number of Trades
2,521
Liquidity & Number of Trades
As of Apr 9, 2025
Liquidity
Slightly High
1-Year Average
724
1-Year High Nov 12, 2024
2,668
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 8,800 44,500 5.06
Mar 28, 2025 9,500 76,500 8.05
Mar 21, 2025 14,300 65,500 4.58
Mar 14, 2025 11,400 59,000 5.18
Mar 7, 2025 11,400 67,300 5.90
Company Profile
KAKEN PHARMACEUTICAL CO.,LTD. is a mid-sized pharmaceutical company. Its main products include joint function improvement agents and onychomycosis medications. The company also develops generic drugs and agricultural chemicals.
Sector
Pharmaceuticals
KAKEN PHARMACEUTICAL CO.,LTD. primarily engages in the pharmaceutical business, manufacturing and selling pharmaceuticals, medical devices, and agricultural chemicals. The company operates as a group that includes itself and two consolidated subsidiaries. In the pharmaceutical segment, Kaken Pharma and Asam handle manufacturing and sales. Additionally, the company is involved in the real estate business. The group as a whole focuses on the medical field while diversifying into areas such as agriculture. As a mid-sized player in the pharmaceutical industry, KAKEN PHARMACEUTICAL CO.,LTD. has established a unique product lineup and business structure, with its main products including the joint function improvement agent "ARTZ" and the onychomycosis treatment "Clenafin."